iSIA Bio-technology
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech innovator developing next-generation antibody and cell therapies for oncology.
Oncology
Technology Platform
Proprietary platforms for designing next-generation antibodies (bispecifics, ADCs) and engineering allogeneic CAR-T and CAR-NK cell therapies.
Opportunities
Potential to address the large unmet need in solid tumor immunotherapy with a scalable, off-the-shelf cell therapy product.
Risk Factors
High technical and clinical risk associated with pioneering allogeneic cell therapies, particularly for solid tumors.
Competitive Landscape
Operates in the highly competitive and capital-intensive field of cell therapy, racing against numerous peers to bring allogeneic products to market.